<DOC>
	<DOCNO>NCT01775891</DOCNO>
	<brief_summary>Investigators hypothesize use Pilsicainide radiofrequency ablation AF could reduce incidence recurrence atrial arrhythmia follow compare class IC antiarrhythmic drug .</brief_summary>
	<brief_title>Efficacy Pilsicainide After Radiofrequency Ablation Paroxysmal Atrial Fibrillation</brief_title>
	<detailed_description>Catheter ablation become integral part management atrial fibrillation ( AF ) , strategy preserve normal sinus rhythm require . However , recurrence atrial arrhythmias common AF ablation . In order prevent arrhythmia recurrence , antiarrhythmic drug ( AADs ) often resume empirically AF ablation . Previously prospective randomize trial demonstrate treatment AADs first 6-weeks AF ablation reduce incidence clinically significant atrial arrhythmia need cardioversion hospitalization arrhythmia management . Pilsicainide class IC antiarrhythmic drug originally develop Japan , pure sodium channel block action slow recovery pharmacokinetics . Its mechanism action appear provide new insight pharmacological conversion AF . In experimental study , pilsicainide potent depressant effect intra-atrial conduction prolong effect atrial effective refractory period ( ERP ) . Theoretically suppression conduction velocity minimize prolongation wavelength induce increase ERP may thus serve allow continuation multiple re-entrant wavelet . Iwasa et al demonstrate pilsicainide effective terminate vagally induce AF propafenone , despite great effect propafenone wavelength , suggest suppression conduction velocity may play important role terminate AF . Moreover , Wijffels et al report pharmacological cardioversion AF explain prolongation wavelength . The effect single oral treatment pilsicainide compare disopyramide infusion multicentre trial . Seventy two patient symptomatic paroxysmal AF randomise receive either single oral dose pilsicainide ( 100-150mg ) infusion disopyramide ( 2 mg/kg ; maximum dose = 100mg ) . In pilsicainide group , cumulative percentage conversion sinus rhythm within 120 minute high disopyramide ( 73 % vs 56 % ) . Moreover , conversion time pilsicainide short class IC antiarrhythmic , include flecainide propafenone , patient recent-onset AF . This seem likely due favorable pharmacokinetics pilsicainide , include rapid absorption gastrointestinal tract , absence change first-pass effect , short elimination half-life . In case unsuccessful ablation AF , AADs ineffective ablation sometimes effective . The effect mechanisms hybrid therapy pilsicainide PV isolation AF assess . Seventy four patient paroxysmal AF pilsicainide ineffective underwent PV isolation . A second PV isolation perform 31 patient among 42 recurred patient ( 57 % ) . Pilsicainide re-administered recurred patient even second session . Amng 21 patient recurrence AF , pilsicainide eliminate AF 11 patient ( success hybrid therapy 86 % ) . In patient paroxysmal AF , pilsicainide significantly prolong ERP distal pulmonary vein ( PV ) , PV-left atrium ( LA ) junction LA , conduction time distal PV PV-LA junction . In patient , PV-LA conduction block observe pilsicainide-induced termination AF ; isolation PV may provide new insight mechanism pharmacological conversion AF . Hybrid therapy pilsicainide PV isolation ( radiofrequency catheter ablation ) appear effective therapeutic approach AF . The pharmacological PV isolation pilsicainide suppression focal discharge atrial tissue may prevent development AF unsuccessful ablation . These mechanism make suitable hybrid therapy catheter ablation PVs . Therefore investigator hypothesize use Pilsicainide radiofrequency ablation AF could reduce incidence recurrence atrial arrhythmia follow compare AADs . Furthermore , seek identify whether clinical predictor AF recurrence 1-year follow-up relationship early recurrence blank period recurrence 1-year follow .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Polystyrene sulfonic acid</mesh_term>
	<mesh_term>Pilsicainide</mesh_term>
	<mesh_term>Flecainide</mesh_term>
	<mesh_term>Anti-Arrhythmia Agents</mesh_term>
	<mesh_term>Lidocaine</mesh_term>
	<mesh_term>Propafenone</mesh_term>
	<criteria>patient drugrefractory paroxysmal atrial fibrillation require catheter ablation patient age 1880 agree study patient agree study patient history catheter ablatio surgery atrial fibrillation patient experienced side effect pilsicainide patient galactose intolerance , Lapp lactase deficiency glucosegalactose malabsorption patient congestive heart failure ejection fraction &lt; 40 % decompensated heart failure patient significant coronary artery disease , liver/renal disease patient kinds arrhythmic require active treatment contraindication warfarin therapy life expectancy &lt; 1 year ] pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>pilsicainide</keyword>
	<keyword>class IC antiarrhythmic drug</keyword>
	<keyword>paroxysmal atrial fibrillation</keyword>
	<keyword>catheter ablation</keyword>
</DOC>